XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 6 Months Ended
Oct. 01, 2022
Oct. 02, 2021
Cash Flows from Operating Activities:    
Net income $ 53,074 $ 10,402
Non-cash items:    
Depreciation and amortization 45,883 48,567
Impairment of assets 94 5,144
Share-based compensation expense 11,034 12,807
Amortization of deferred finance costs 313 1,813
(Benefit) provision for losses on inventory (1,529) 114
Gain on closing of transaction 382 9,603
Contingent consideration expense (504) 9,345
Other non-cash operating activities (1,186) 7,054
Change in operating assets and liabilities:    
Change in accounts receivable (17,043) (14,574)
Change in inventories 35,990 (5,475)
Change in prepaid income taxes 2,145 2,477
Change in other assets and other liabilities (7,724) (842)
Change in accounts payable and accrued expenses 8,867 (25,449)
Net cash provided by operating activities 129,032 41,780
Cash Flows from Investing Activities:    
Capital expenditures (81,424) (34,731)
Acquisition (2,850) (2,500)
Proceeds from divestiture 850 0
Proceeds from sale of property, plant and equipment 7,537 860
Other investments (13,395) 0
Net cash used in investing activities (89,282) (36,371)
Cash Flows from Financing Activities:    
Term loan borrowings 280,000 0
Term loan redemption (280,000) 0
Proceeds from revolving facility 50,000 0
Repayment of term loan borrowings (6,125) (8,750)
Debt issuance costs (1,118) 0
Share repurchases (75,000) 0
Contingent consideration payments (21,593) 0
Proceeds from employee stock purchase plan 2,459 2,210
Proceeds from exercise of stock options 2,319 1,569
Other (23) 22
Net cash used in financing activities (49,081) (4,949)
Effect of exchange rates on cash and cash equivalents (8,965) (345)
Net Change in Cash and Cash Equivalents (18,296) 115
Cash and Cash Equivalents at Beginning of Period 259,496 192,305
Cash and Cash Equivalents at End of Period 241,200 192,420
Supplemental Disclosures of Cash Flow Information:    
Transfers from inventory to fixed assets for placement of Haemonetics equipment $ 66,452 $ 10,139